Search - tctmd.com

Displaying 321 - 340 of 491

Sort: Relevancy | Date

Presentation TCT 2015

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Presenter: Gerhard C. Schuler, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

Presentation TCT 2015

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Presenter: Jacqueline Saw, Steven J. Yakubov, Matthew J. Price

October 13, 2015

Presentation TCT 2015

TCT 53: Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Intracranial Bleeding Results From the Amplatzer Cardiac Plug Registry

Presenter: Jacqueline Saw, Steven J. Yakubov, Apostolos Tzikas

October 13, 2015

Presentation TCT 2015

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Presenter: George D. Dangas, Paul A. Gurbel, C. Michael Gibson

October 13, 2015

Presentation TCT 2015

Outcome of Patients With Atrial Fibrillation and Stent Implantation: Results of the Prospective LASER Registry

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Uwe Zeymer

October 11, 2015

Presentation TCT 2015

Weighing the Risk of Stroke in Atrial Fibrillation vs the Risk of Bleeding on Anticoagulation

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Neal S. Kleiman

October 11, 2015

Presentation

Baseline Characteristics and Prognostic Implications of Preexisting and New-Onset A-fib After TAVR

Presenter: R. Chopard

August 27, 2015

Presentation

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

Presenter: Connie N. Hess

August 03, 2015

Presentation

Perioperative Bridging Anticoagulation in Patients With A-fib

Presenter: JD. Douketis

July 09, 2015

Presentation

Meta-analysis: LAA Closure as an Alternative to Warfarin for Stroke Prevention in A-fib

Presenter: David R. Holmes Jr

June 16, 2015

Presentation

A-fib and Risk of STEMI vs NSTEMI

Presenter: Elsayed Z. Soliman

May 06, 2015

Advertisement

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Reversal Agents for Factor Xa Inhibitors

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

TCT 53: Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Intracranial Bleeding Results From the Amplatzer Cardiac Plug Registry

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Outcome of Patients With Atrial Fibrillation and Stent Implantation: Results of the Prospective LASER Registry

Weighing the Risk of Stroke in Atrial Fibrillation vs the Risk of Bleeding on Anticoagulation

Baseline Characteristics and Prognostic Implications of Preexisting and New-Onset A-fib After TAVR

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

Perioperative Bridging Anticoagulation in Patients With A-fib

Meta-analysis: LAA Closure as an Alternative to Warfarin for Stroke Prevention in A-fib

A-fib and Risk of STEMI vs NSTEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content